Hyderabad: Bharat Biotech of Hyderabad announced the successful shipment of its Covaxin COVID-19 vaccine to 11 cities in India. It also said that the Central Government has been donating 16.5 lakh doses.
Bharat Biotech delivered the first batch of vaccines (each vial containing 20 doses) to Ganavaram, Guwahati, Patna, Delhi, Kurukshetra, Bangalore, Pune, Bhubaneswar, Jaipur, Chennai, and Lucknow after receipt of the government purchase order for 55 lakh doses. Although some shipments have arrived in the respective cities, later this evening others will be shipped.
The company also expressed its deepest gratitude for making this a fruitful public-private collaboration for the production of India’s first COVID-19 vaccine to the country, the clinical trial volunteers, and its partners.
In collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology, Bharat Biotech’s Covaxin is India’s first indigenous COVID-19 vaccine (NIV). This indigenous, inactivated vaccine is developed and produced in the world’s one-of-its-kind BSL-3 (Bio-Safety Level 3) biocontainment facility of Bharat Biotech.
Initial human trial evaluation of Covaxin resulted in many specific product features, including long-term durability of immune responses to multiple viral proteins as opposed to spike proteins only, and demonstrated wide spectrum neutralization capabilities with heterologous strains of SARS-CoV-2, potentially reducing or eliminating escape mutants.
Covaxin is a highly purified and inactivated two-dose SARS-CoV-2 vaccine developed on a platform for the production of Vero cells with an outstanding safety record of over 300 million doses.
The vaccine has also shown that its multiple epitopes can produce memory T cell responses, suggesting durability and rapid antibody response to potential infections.
Its most important feature is its proven safety profile, which is substantially lower than several other published vaccines. (INN)